Cartesian Therapeutics, Inc. (RNAC)
8.03
+0.17
(+2.16%)
USD |
NASDAQ |
Sep 18, 16:00
8.11
+0.08
(+1.00%)
After-Hours: 20:00
Cartesian Therapeutics Enterprise Value : 157.45M for Sept. 18, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 18, 2026 | 157.45M |
| September 17, 2026 | 152.35M |
| September 16, 2026 | 153.85M |
| September 15, 2026 | 153.25M |
| September 14, 2026 | 157.75M |
| September 11, 2026 | 162.26M |
| September 10, 2026 | 169.47M |
| September 09, 2026 | 177.28M |
| September 08, 2026 | 185.09M |
| September 04, 2026 | 194.70M |
| September 03, 2026 | 190.19M |
| September 02, 2026 | 188.99M |
| September 01, 2026 | 195.60M |
| August 31, 2026 | 195.00M |
| August 28, 2026 | 204.61M |
| August 27, 2026 | 215.73M |
| August 26, 2026 | 222.33M |
| August 25, 2026 | 228.04M |
| August 24, 2026 | 218.43M |
| August 21, 2026 | 217.83M |
| August 20, 2026 | 223.54M |
| August 19, 2026 | 231.35M |
| August 18, 2026 | 192.60M |
| August 17, 2026 | 192.00M |
| August 14, 2026 | 181.78M |
| Date | Value |
|---|---|
| August 13, 2026 | 178.18M |
| August 12, 2026 | 176.83M |
| August 11, 2026 | 174.12M |
| August 10, 2026 | 179.38M |
| August 07, 2026 | 182.08M |
| August 06, 2026 | 179.38M |
| August 05, 2026 | 167.06M |
| August 04, 2026 | 158.35M |
| August 03, 2026 | 152.65M |
| July 31, 2026 | 150.54M |
| July 30, 2026 | 148.44M |
| July 29, 2026 | 139.13M |
| July 28, 2026 | 146.04M |
| July 27, 2026 | 150.24M |
| July 24, 2026 | 152.95M |
| July 23, 2026 | 154.15M |
| July 22, 2026 | 160.46M |
| July 21, 2026 | 160.46M |
| July 20, 2026 | 161.96M |
| July 17, 2026 | 164.36M |
| July 16, 2026 | 166.46M |
| July 15, 2026 | 176.98M |
| July 14, 2026 | 175.17M |
| July 13, 2026 | 175.47M |
| July 10, 2026 | 200.41M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Allogene Therapeutics, Inc. | 330.04M |
| Beam Therapeutics, Inc. | 1.671B |
| Kyverna Therapeutics, Inc. | 272.57M |
| Arrowhead Pharmaceuticals, Inc. | 9.157B |
| Oncolytics Biotech, Inc. | 92.30M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 13.72M |
| Total Expenses (Quarterly) | -13.72M |
| EPS Diluted (Quarterly) | 0.4595 |
| Earnings Yield | -73.96% |
| Normalized Earnings Yield | -50.52 |